309 related articles for article (PubMed ID: 29258361)
1. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin use in an academic medical centre and associated cost savings.
Streifel AC; Sikka MK; Bowen CD; Lewis JS
Int J Antimicrob Agents; 2019 Nov; 54(5):652-654. PubMed ID: 31398481
[TBL] [Abstract][Full Text] [Related]
3. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Soriano A; Rossolini GM; Pea F
Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
[No Abstract] [Full Text] [Related]
4. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Scott LJ
Drugs; 2015 Jul; 75(11):1281-91. PubMed ID: 26105117
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.
Leuthner KD; Yuen A; Mao Y; Rahbar A
Expert Rev Anti Infect Ther; 2015 Feb; 13(2):149-59. PubMed ID: 25578881
[TBL] [Abstract][Full Text] [Related]
10. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
11. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries.
Marcellusi A; Viti R; Sciattella P; Sarmati L; Streinu-Cercel A; Pana A; Espin J; Horcajada JP; Favato G; Andretta D; Soro M; Andreoni M; Mennini FS
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):581-599. PubMed ID: 30714834
[No Abstract] [Full Text] [Related]
15. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
17. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
Kim A; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections.
Roecker AM; Pope SD
Expert Opin Pharmacother; 2008 Jul; 9(10):1745-54. PubMed ID: 18570607
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
